样式: 排序: IF: - GO 导出 标记为已读
-
Reply to: Letter to the Editor from Malik et al.: Acute kidney injury following subcutaneous meloxicam administration J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2024-03-11 Alex Krekis, Jonathan N. King, Duncan D'Arcy‐Howard, Nadene Stapleton, Jonathan Elliott, Ludovic Pelligand
-
-
Pharmacokinetic report: Pharmacokinetics of a single oral dose of gabapentin in goats (Capra hircus) J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2024-03-02 Michael D. Kleinhenz, Darian Davis, Mikaela M. Weeder, Alyssa Leslie, Emily J. Reppert, Kushan Kompalage, Ryan Tucker, Johann F. Coetzee
Gabapentin is used in goats to treat chronic pain associated with lameness. However, pharmacokinetic data and clinical effectiveness trials are lacking. The objective of the study was to describe the pharmacokinetics of gabapentin in goats following a single oral dose. Six Spanish‐crossbred goats were enrolled. Each goat was administered gabapentin at a target dose of 15 mg/kg per os. Serial blood
-
Letter to the Editor: Acute kidney injury following subcutaneous meloxicam administration J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2024-03-01 Richard Malik, Matthew K. Wun, Terence King, Rachel Korman
-
Florfenicol urinary excretion and its potential for treating canine urinary tract infections J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2024-02-29 Kate S. KuKanich, Elayna E. Anderson, Astrid D. Carcamo Tzic, Butch KuKanich
The canine urinary excretion of florfenicol was evaluated to explore its potential for treating urinary tract infections. Nine healthy male intact purpose‐bred Beagles and four healthy client‐owned dogs each received a single oral dose of florfenicol 20 mg/kg (300 mg/mL parenteral solution) with food. All voluntary urinations were collected for 12 h. Although florfenicol is reportedly bitter tasting
-
Pharmacokinetic evaluation of oral deracoxib in geese (Anser anser domesticus) J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2024-02-29 Charbel Fadel, Beata Łebkowska‐Wieruszewska, Amnart Poapolathep, Firas Serih, Krzysztof Bourdo, Mario Giorgi
The integration of pain management in veterinary practice, driven by heightened animal welfare concerns, extends to avian species where subtle and nonspecific behavioral signs pose challenges. Given that safety concerns with classical NSAIDs highlight the need for more targeted alternatives in birds, this study explores the pharmacokinetic (PK) properties of Deracoxib (DX), a COX‐2 selective NSAID
-
Comparison of solubility profiles for pioneer and generic monensin premixes in biorelevant simulated intestinal fluid based on shake flask extractions J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2024-02-26 Beverly J. Krabel, Laura B. Foust, Gary B. Fuller, Robert P. Hunter
In the United States, a generic Type A medicated article product can gain the FDA approval by demonstrating bioequivalence (BE) to the pioneer product by successfully conducting a blood level, pharmacodynamic, or clinical BE study. A biowaiver can be granted based on several criteria, assuming the dissolution of the test and reference products represents the only factor influencing the relative bioavailability
-
Bayesian estimation in veterinary pharmacology: A conceptual and practical introduction J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2024-02-22 Andrew P. Woodward
Sophisticated mathematical and computational tools have become widespread and important in veterinary pharmacology. Although the theoretical basis and practical applications of these have been widely explored in the literature, statistical inference in the context of these models has received less attention. Optimization methods, often with frequentist statistical inference, have been predominant.
-
Application of eprinomectin-containing parasiticides at label doses causes neurological toxicosis in cats homozygous for ABCB11930_1931del TC J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2024-02-17 Katrina L. Mealey, Neal S. Burke, Nicolas F. Villarino, Michael H. Court, Jennifer P. Heusser
The feline MDR1 mutation (ABCB11930_1931delTC) has been associated with neurological toxicosis after topical application of eprinomectin products labeled for feline use. Information was collected from veterinarians who submitted samples for ABCB11930_1931delTC genotyping. In most cases, the submission form indicated an adverse event involving eprinomectin, in other cases submitting veterinarians were
-
Safety and immunogenicity of an adjuvanted recombinant spike protein-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, SpikeVet™, in selected Carnivora, Primates and Artiodactyla in Australian zoos J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2024-02-12 David J. McLelland, Michael Lynch, Larry Vogelnest, Paul Eden, Alisa Wallace, Jayne Weller, Sam Young, Rebecca Vaughan-Higgins, Anna Antipov, Yoshikazu Honda-Okubo, Nikolai Petrovsky
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can infect a broad range of animal species and has been associated with severe disease in some taxa. Few studies have evaluated optimal strategies to mitigate the risk to susceptible zoo animals. This study evaluated the safety and immunogenicity of a protein-based veterinary SARS-CoV-2 vaccine (SpikeVet™) in zoo animals. Two to three doses
-
The effects of food on the pharmacokinetics of mycophenolate mofetil in healthy horses J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2024-02-09 Kaitlyn Bello, Gwendolen Lorch, Mark G. Papich, Kyeongmin Kim, Ramiro E. Toribio, Liwei Yan, Zhiliang Xie, Kasey Hill, Mitch A. Phelps
Additional immunomodulatory treatment is needed for the management of immune-mediated disease in horses. Mycophenolate mofetil (MMF) is an immunomodulatory agent used in human and veterinary medicine for the prevention of graft rejection and the management of autoimmune diseases. Few studies exist investigating the pharmacokinetics of MMF in horses. The aim of this study was to evaluate the pharmacokinetics
-
Effect of meloxicam or robenacoxib administration timing on renal function and postoperative analgesia in cats undergoing ovariohysterectomy: A randomized, blinded, controlled clinical trial J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2024-01-18 Alex Krekis, Jonathan N. King, Duncan D'Arcy-Howard, Nadene Stapleton, Jonathan Elliott, Ludovic Pelligand
We evaluated the effect of administration timing of meloxicam and robenacoxib on renal function, platelet cyclo-oxygenase and perioperative analgesia in 60 cats undergoing ovariohysterectomy, in a prospective randomized blinded controlled study. Twelve cats were randomly allocated to one subcutaneous treatment group: meloxicam (0.2 mg/kg) or robenacoxib (2 mg/kg) at admission (MA, RA), at induction
-
Pharmacokinetics of intranasal and intramuscular flunixin in healthy grower pigs J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2024-01-11 Emily E. Wiloch, Hiroko Enomoto, Lilly Smith, Ronald E. Baynes, Kristen M. Messenger
Flunixin meglumine is a nonsteroidal anti-inflammatory drug approved to manage pyrexia associated with swine respiratory disease. In the United States, no analgesic drugs are approved for use in swine by the FDA, although they are needed to manage painful conditions. This study evaluated the pharmacokinetics and relative bioavailability of intranasal versus intramuscular flunixin in grower pigs. Six
-
Effect of clodronate on gene expression in the peripheral blood of horses J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2024-01-10 Callie V. Wilcox, Heather K. Knych, Scott A. Katzman, Rick M. Arthur, Veronika Rodriguez, Carrie J. Finno
There are two FDA-approved bisphosphonate products, clodronate (Osphos®) and tiludronate (Tildren®), for use in horses. It is hypothesized that bisphosphonates can produce analgesic effects and prevent proper healing of microcracks in bone. Therefore, bisphosphonate use is banned in racehorses. However, bisphosphonates have a short detection window in the blood before sequestration in the skeleton
-
Enrofloxacin pharmacokinetics in yellow catfish (Pelteobagrus fulvidraco): A comparative analysis of oral, intramuscular, and bath administration J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2024-01-08 Bofan Jia, Yang Zhao, Jianchao Deng, Shengjun Chen, Chunsheng Li, Bo Qi, Xiao Hu, Laihao Li
Enrofloxacin (ENR) residues in yellow catfish (Pelteobagrus fulvidraco) often exceed the standard due to excessive use. This study explored the pharmacokinetics of ENR and its metabolite ciprofloxacin (CIP) in yellow catfish following a single dose of 10 mg/kg body weight via intramuscular injection (IM), oral gavage (PO), or a 5-h drug bath at 10 mg/L and 25°C. High-performance liquid chromatography-mass
-
A dose characterization study evaluating the pharmacodynamics and safety of a concentrated alfaxalone solution (4%) as an intramuscular sedative in dogs J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-12-27 Ting Michelle Angel Yvonne Hoon, Irving Tjiah Wern Kat, Kirby Pasloske, Trisha Farry, Wendy Anne Goodwin
Alfaxalone is a commonly employed veterinary anaesthetic induction and sedation agent. A 4% w/v preserved, aqueous formulation of alfaxalone ‘RD0387’ (A4%) has recently been developed. To evaluate the sedative effects of A4%, three doses, 5 mg kg−1 (A5); 7.5 mg kg−1 (A7.5) and 10 mg kg−1 (A10) were administered intramuscularly into the epaxial musculature of six healthy adult mixed-breed dogs in an
-
Pharmacokinetics of meloxicam following intravenous administration at different doses in sheep J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-11-30 Huseyin Gungor, Orhan Corum, Duygu Durna Corum, Alper Serhat Kumru, Gökhan Yilmaz, Devran Coskun, Alparslan Coskun, Kamil Uney
The aim of this study is to determine the pharmacokinetic change after intravenous administration of meloxicam at doses of 0.5, 1 and 2 mg/kg to sheep. The study was carried out on six Akkaraman sheep. Meloxicam was administered intravenously to each sheep at 0.5, 1, and 2 mg/kg doses in a longitudinal pharmacokinetic design with a 15-day washout period. Plasma concentrations of meloxicam were determined
-
Letter to the editor J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-12-04 Ching-Fen Wu, Tirawat Rairat, Chi-Chung Chou, Hung-Chih Kuo
CONFLICT OF INTEREST STATEMENT The authors declare no conflict of interest.
-
Metronidazole pharmacokinetics in geese (Anser anser domesticus) after intravenous and oral administrations J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-11-30 Charbel Fadel, Beata Łebkowska-Wieruszewska, Krzysztof Bourdo, Amnart Poapolathep, Georges Hassoun, Mario Giorgi
Metronidazole (MTZ) is a 5-nitroimidazole anti-bacterial and anti-protozoal drug. In human and companion animal medicine, MTZ remains widely used due to its effectiveness against anaerobic bacteria and protozoa. In farm animals, however, MTZ is currently prohibited in several countries due to insufficient data on nitroimidazoles. The purpose of this study was to assess its pharmacokinetics (PK) in
-
Pharmacokinetics of doxycycline hyclate in pigs with a new feed premix formulation J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-11-28 Mónica Zermeño-Acosta, Héctor Sumano, Jorge Luna-del Villar, Maria Josefa Bernad, Lilia Gutiérrez
This study aimed to evaluate the administration of doxycycline hyclate in a long-acting pharmaceutical preparation in pigs when administered either ad libitum as a feed medication or an oral bolus dose. In all instances, the studied dose was 20 mg/kg b.w. A total of 48 healthy crossbred, castrated male pigs (Landrace-Yorkshire) weighing 23 ± 4.3 kg were included in this trial. They were randomly assigned
-
Pharmacokinetics of gamma-hydroxybutyric acid in 6-week-old swine (Sus scrofa domesticus) after intravenous and oral administration J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-11-20 Charlotte Cuypers, Mathias Devreese, Katleen Van Uytfanghe, Christophe Stove, Stijn Schauvliege
Sedative as well as protective effects during hypoxia have been described for gamma-hydroxybutyric acid (GHB). Six swine (Sus scrofa domesticus) of 6 weeks old were administered NaGHB at a dose of 500 mg/kg intravenously (IV) and 500 and 750 mg/kg orally (PO) in a triple cross-over design. Repeated blood sampling was performed to allow pharmacokinetic analysis of GHB. Whole blood concentration at time
-
Depletion of tilmicosin residue in Gushi chickens following oral administration via drinking water J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-11-10 Mei Zhang, Kun Qian, Guang-Hui Li, Ming-Hui Duan, Ze-En Li, Yan Dai, Jun-Cheng Chen, Fan Yang
This study aimed to examine the depletion of tilmicosin residues in Gushi chickens following the administration at a concentration of 75 mg/L in their drinking water for three consecutive days. Plasma, liver, kidney, lung, muscle, and skin + fat samples were collected from 6 chickens at 6 h, 1, 3, 5, and 7 days after the treatment. Tilmicosin concentrations in the samples were determined using a high-performance
-
Correlation of opioid antinociception and hypothermia in dogs—An animal welfare refinement J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-11-06 Butch KuKanich, Kate KuKanich, Astrid D. Carcamo Tzic, Elayna E. Anderson
The purpose of this study was to assess antinociception and correlation of antinociception and hypothermic effects after intravenous opioids in dogs. Nine healthy male Beagles were enrolled in the study. They were acclimated to a thermal nociceptive device, then received three IV treatments (saline, butorphanol 0.4 mg/kg and methadone 0.5 mg/kg) in a randomized complete block design. Rectal temperature
-
Pharmacokinetics of letrozole and effects of its increasing doses on gonadotropins in ewes during the breeding season J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-11-03 Mehmet Bugra Kivrak, Orhan Corum, Murat Yuksel, Erdinc Turk, Duygu Durna Corum, Ibrahim Ozan Tekeli, Kamil Uney
Letrozole is a non-steroidal, third-generation aromatase inhibitor used in humans. Although letrozole is not approved for use in animals, it is used off-label in cases of synchronization and infertility. The aim of this study was to determine the pharmacokinetics of letrozole after a single intravenous administration at three different doses in ewes during the breeding season and its effect on gonadotropins
-
Pharmacokinetics of meloxicam in pre-ruminant calves after intravenous, oral, and subcutaneous administration J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-10-28 Annemari Jokela, Alexandra Nyrhilä, Magdy Adam, Kati Salla, Marja Raekallio, Riikka Aho, Marianna Norring, Ann-Helena Hokkanen
Meloxicam is routinely used for pain alleviation in pre-ruminant calves during husbandry procedures. The pharmacokinetics of a single dose (0.5 mg/kg) of meloxicam was investigated after intravenous (IV), subcutaneous (SC), and oral (PO) administration in 30 pre-ruminant calves. Each group included 10 calves. Oral meloxicam was administered at least 1 h after feeding. Plasma samples were collected
-
Pharmacokinetics, withdrawal period and risk assessment of enrofloxacin in the northern snakehead (Channa argus) following bath administration J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-10-18 Meiling Zhang, Guangming Zheng, Yi Yin, Hao Zhou, Lisha Ma, Lichun Li, Jiawei Lin, Shugui Liu, Cheng Zhao, Xiaoxin Dai, Linting Wei, Qi Shan
Enrofloxacin (ENR) is widely used in aquaculture practice, but little is known about its pharmacokinetic, withdrawal period and dietary risk in fish via bath administration. The purpose of this study was to provide data support for the use of ENR bath therapy in the northern snakehead (Channa argus). The pilot study was carried out to evaluate the therapy concentrations of ENR in northern snakehead
-
The effects of formulation on the pharmacokinetics of itraconazole and amiodarone in dogs after oral administration of a combination product, commercial products, and compounded products J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-10-11 Robert P. Hunter, Roy Madigan
This study evaluated four different formulations of itraconazole and amiodarone. Formulation 1 was Vida's combination tablet containing both active pharmaceutical ingredients (APIs). Formulation 2 was separate, commercially available human generic capsules and tablets of itraconazole and amiodarone, respectively. Formulation 3 was separate, compounded suspensions of itraconazole and amiodarone. Formulation
-
Plasma pharmacokinetics of clorsulon following administration of a single subcutaneous or intravenous injection to cattle J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-10-12 Steffen Rehbein, Valerie Kvaternick, Michael Kellermann, Dietmar Hamel, Andrea Antretter, Christopher Johnson
The benzenedisulfonamide derivative clorsulon is a potent fasciolicide which is marketed in fixed combination injectables, typically combined with the macrocyclic lactone ivermectin. In the presented pharmacokinetic study, the plasma profile of clorsulon in 32 healthy, young Brown Swiss cattle was administered a single intravenous dose at 3 mg/kg body weight or subcutaneously at 3, 6 or 12 mg/kg body
-
Evaluation of plasma and urine pharmacokinetics of tranexamic acid for equine medication control J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-09-27 Yohei Minamijima, Taisuke Kuroda, Takahiro Kamiya, Yu Sone, Ai Wakuno, Hideki Ito, Motoi Nomura, Gary Ngai-Wa Leung, Kenji Kinoshita, Masayuki Yamada
This study aimed to evaluate the pharmacokinetics (PK) of tranexamic acid (TXA) in horses and estimate its irrelevant plasma and urine concentrations using the pharmacokinetic/pharmacodynamic (PK/PD) approach by applying the Pierre-Louis Toutain model. TXA was intravenously administered to eight thoroughbred mares, and plasma and urine TXA concentrations were quantified by liquid chromatography/tandem
-
Depletion of dexamethasone in cattle: Food safety study in dairy and beef cattle J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-09-26 Al Chicoine, David L. Renaud, Saad S. Enouri, Patricia M. Dowling, Yu Gu, Ron J. Johnson
Dexamethasone is approved for cattle in Canada for several conditions, but no withdrawal times are currently provided on the approved labels. Recently, the list of Maximum Residues Limits for Veterinary Drugs in Foods in Canada was amended to include dexamethasone. The objectives of this study were to determine the residue depletion profile of dexamethasone after an extra-label dosage regimen in milk
-
Safety, tolerability and biological responses of Oreochromis niloticus juveniles upon oral oxolinic acid administration J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-09-22 Thangapalam Jawahar Abraham, Jaykumar Bhagubhai Patel, Avishek Bardhan, Ravindran Rajisha, Satyen Kumar Panda, Prasanna Kumar Patil
In aquaculture, oxolinic acid (OA) is used as a second-line treatment at 12 mg/kg biomass/day for seven consecutive days. The present study evaluated the biosafety of 21 days of dietary administration of OA at 0, 12, 36, 60 and 120 mg by assessing the growth, biochemical, erythrocytic morphological and histopathological alterations and residue levels in Oreochromis niloticus. A significant dose-dependent
-
Disposition kinetics of meloxicam in green sea turtles (Chelonia mydas) after intravenous and intramuscular administrations J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-09-16 Amnart Poapolathep, Oranee Jongkolpath, Mario Giorgi, Narumol Klangkaew, Napasorn Phaochoosak, Thanaphan Chomcheun, Amornthep Archawakulathep, Saranya Poapolathep
The pharmacokinetics were described of meloxicam (MLX) in green sea turtles (Chelonia mydas), following a single intravenous (i.v.) and intramuscular (i.m.) administrations at one of two dosages of 0.1 or 0.2 mg/kg body weight (b.w.). The sample of 20 green sea turtles was divided into four groups (n = 5) using a randomization procedure according to a parallel study design. Blood samples were collected
-
Pharmacokinetics of toltrazuril and its metabolite, toltrazuril sulfone, in suckling piglets following oral and intramuscular administrations J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-08-18 Ta-Wei Yeh, Tirawat Rairat, Chao-Ming Wang, Ching-Fen Wu, Szu-Wei Huang, Chi-Chung Chou, Hung-Chih Kuo
Toltrazuril (TZR) is currently the only registered chemotherapeutic drug in the European Union for the treatment of Cystoisospora suis. This study investigated the comparative pharmacokinetics and tissue concentration-time profiles of TZR and its active metabolite, toltrazuril sulfone (TZR-SO2), after oral (per os, p.o.) and intramuscular (i.m.) administration to suckling piglets. Following a single
-
Pharmacokinetics of a single oral dose of grapiprant in juvenile pigs (Sus scrofa domestica) J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-07-26 Stephanie Kleine, Chiara E. Hampton, Christopher Smith, Genevieve Bussieres, Pierre-Yves Mulon, Reza Seddighi, Sherry Cox, Joe Smith
Both pet and research pigs can suffer from some degree of pain from surgery, injuries, or osteoarthritis (OA). Despite this, there is a paucity of data on safe and effective analgesia agents in pigs. Grapiprant is an EP4 antagonist that blocks the action of the pro-inflammatory prostanoid, PGE2. It has shown efficacy in attenuating pain associated with ovariohysterectomy and OA in dogs. However, there
-
Age-related changes in the pharmacokinetics of meloxicam after intravenous administration in sheep J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-07-24 Devran Coskun, Orhan Corum, Duygu Durna Corum, Gul Cetin, Mehmet Irmak, Hatice Rumeysa Ceyhan, Kamil Uney
The pharmacokinetics of meloxicam was studied in 1-, 6-, and 12-month-old sheep following a single intravenous (i.v.) dose of 1 mg/kg. The experiments were carried out when the Romanov sheep were 1 month old (7.93 ± 0.91 kg), 6 months old (27.47 ± 4.91 kg), and 12 months old (37.10 ± 3.64 kg). Meloxicam concentration in plasma was determined by high-performance liquid chromatography and the data collected
-
Cannabidiol and cannabidiolic acid: Preliminary in vitro evaluation of metabolism and drug–drug interactions involving canine cytochrome P-450, UDP-glucuronosyltransferase, and P-glycoprotein J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-07-19 Michael H. Court, Katrina L. Mealey, Neal S. Burke, Tania Perez Jimenez, Zhaohui Zhu, Joseph J. Wakshlag
Phytocannabinoid-rich hemp extracts containing cannabidiol (CBD) and cannabidiolic acid (CBDA) are increasingly being used to treat various disorders in dogs. The objectives of this study were to obtain preliminary information regarding the in vitro metabolism of these compounds and their capacity to inhibit canine cytochrome P450 (CYP)-mediated drug metabolism and canine P-glycoprotein-mediated transport
-
Determination of temporal changes in hepatic drug-oxidizing capacity using plasma metabolite/caffeine ratios in non-pregnant and pregnant goats J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-07-12 Feray Altan, Sakine Ulkum Cizmeci, Ayse Merve Kose, Orhan Corum, Kamil Uney
Caffeine (CF) is a metabolic probe drug used in the determination of the hepatic drug-oxidizing capacity. The aim of this study was to investigate temporal changes in the hepatic drug-oxidizing capacity using plasma metabolite/CF ratios in non-pregnant goats (n = 11) and pregnant goats (n = 23). CF (5 mg/kg, intravenous) was administered in six periods (Period 1–6) with 45 days between two periods
-
Pharmacokinetic disposition of marbofloxacin after intramuscular administration in estuarine crocodiles (Crocodylus porosus) J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-06-28 Mona Yalong, Saranya Poapolathep, Mario Giorgi, Kraisiri Khidkhan, Narumol Klangkaew, Napasorn Phaochoosak, Narongsak Chaiyabutr, Tara Wongwaipairoj, Amnart Poapolathep
To date, the pharmacokinetics of fluoroquinolones in estuarine crocodiles (Crocodylus porosus) have been reported for enrofloxacin but not for marbofloxacin (MBF), which is a broad-spectrum antibiotic used only in veterinary medicine. This study investigated the pharmacokinetics of MBF after intramuscular administration at two difference dosages (2 and 4 mg/kg body weight) in estuarine crocodiles and
-
Pharmacokinetics of oral tapentadol in cats J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-06-23 J. Lakritz, T. K. Aarnes, B. Alva, J. Howard, G. Magnin, P. Lerche, B. Kukanich
To evaluate pharmacokinetics of one dose of tapentadol hydrochloride orally administered to cats. Prospective experimental study. Five healthy adult mixed-breed cats. Each cat received 18.8 ± 1.0 mg/kg tapentadol orally. Venous blood samples were collected at time 0 (immediately prior to administration of tapentadol) 1, 2, 5, 10, 15, 30, 45, 60, 90 min, and 2, 4, 8, 12 to 24 h after drug administration
-
Introduction J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-06-11
This Supplement to the Journal of Veterinary Pharmacology and Therapeutics (JVPT) is dedicated to the Proceedings of our 15th International Congress of the European Association for Pharmacology and Toxicology (EAVPT). EAVPT congresses traditionally have been held every 3 years as the leading international convention of Veterinary Pharmacologists, Toxicologists, Regulators and Specialist Clinicians
-
I0 | One Health: Our Health, Our Animals. Our Environment – The economics of health and scarcity in the context of a changing world J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-06-11
L. Reeve-Johnson Faculty of Science, Health, Education and Engineering, University of Sunshine Coast, Maroochydore Queensland, Australia; President European Association of Veterinary Pharmacology and Toxicology The ‘One Health’ approach implies multiple stakeholders with different perceptions of utility interacting daily in the highly complex system of healthcare delivery. As we attempt to adopt increasingly
-
I1 | New regulations on veterinary medicinal products – Impact on veterinary medicine J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-06-11
N. De Briyne Federation of Veterinarians of Europe In 2021, two new Regulations covering veterinary medicines came into force in the European Union. The EU Veterinary Medicines Regulation 2019/6, which replaces the previous Veterinary Medicines Directive, introduces several changes to improve the availability, safety, and efficacy of veterinary medicines in the European Union. Some of the key changes
-
I2 | The availability and use of antimicrobial agents J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-06-11
E. Hamelin World Organization for Animal Health (WOAH), Sub-Regional Representation, Brussels, Belgium The World Organization for Animal Health (WOAH, founded as OIE) is a standard setting intergovernmental organization working across borders with the mandate to improve animal health, welfare and veterinary public health. The fight against AMR needs global and coordinated solutions. WOAH is in the
-
I3 | Environmental risk assessment of veterinary medicines: Current situation and future prospects J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-06-11
R. Carapeto Agencia española de medicamentos y productos sanitarios (AEMPS) Classified one decade ago as emergent pollutants, the pharmaceutical residues have been under study by researchers worldwide for a long time. The information gathered during that time has resulted in evidence-based policy action that is progressively changing the way these substances are regulated and controlled. In the last
-
I4 | Regulatory challenges – My personal perspective* J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-06-11
M. Martinez US FDA, Office of New Animal Drug Evaluation and Research *The perspectives provided in this abstract have not been formally disseminated by the Food and Drug Administration and should not be construed to represent any Agency endorsement, determination, or policy. As regulators, we are impacted by the rapid changes in medical needs and expectations, societal perspectives, and technology
-
I5 | Poultry feather analysis: A potential tool for assessing compliance with antimicrobial use policies? J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-06-11
J. Cornejo Kelly1,2; E. Pokrant1,2; A. Maddaleno1 1Laboratory of Veterinary Pharmacology FARMAVET, Faculty of Veterinary and Livestock Sciences FAVET; 2Laboratory of Food Safety LIA, Faculty of Veterinary and Livestock Sciences FAVET, La Pintana, Santiago, Chile With billions of food animals produced globally, as much as 37% of broiler chickens, 44% of pigs, and 49% of cattle are inedible to humans
-
I6 | Biosecurity in animal production to improve health and reduce antimicrobial use J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-06-11
J. Dewulf Veterinary Epidemiology Unit, Department of Internal Medicine, Reproduction and Population Medicine, Faculty of Veterinary Medicine, Ghent University, Ghent, Belgium Introduction: Farm animals such as pig, poultry and cattle are susceptible to a wide range of diseases, including zoonotic infections, which can affect health, welfare and productivity, and thereby have a major economic impact
-
I7 | Disinfectants as cornerstones of one health approaches in veterinary medicine J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-06-11
P. Sanders1; C. Soumet2 1Strategy and Programme Department, Maisons-Alfort; 2Laboratory of Fougères, Anses, Fougères, France Controlling infectious diseases in livestock and preventing the transmission of zoonotic agents to professionals and end consumers require the use of disinfection. Disinfection is part of the procedures applied in biosecurity protocols in livestock farming, but also in veterinary
-
I8 | Competency based learning in veterinary undergraduate curriculum: Lessons learned J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-06-11
T. Van Haeften; J. Ijzer Faculty of Veterinary Medicine, Utrecht University, The Netherlands With the introduction of the bachelor-master curricula in 2001, it was decided that competency-based education, in alignment with our educational philosophy, should form the backbone of the study in veterinary medicine at Utrecht University. Curriculum outcomes were based upon and aligned with the VetPro competency
-
I9 | Prescribing and therapeutic decision-making as an essential competence in medical and veterinary education J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-06-11
D. Brinkman Internal Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands During this talk, the newest insights in the teaching and assessment of prescribing competence will be discussed. What can we learn from the experiences with medical students? What is the best way to teach and assess these skills? What can we learn from previous European projects? Some practical examples
-
I10 | Antimicrobial therapy development: Issues and solutions J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-06-11
S. Soback National Residue Control Laboratory, Kimron Veterinary Institute, Beit Dagan, Israel Introduction: The first antimicrobial agents were introduced to human therapy in the mid-30s (sulfonamides) and during WW2 (penicillin). The use of these drugs in veterinary therapy followed soon after. Tetracycline was introduced in 1954. These 3 classes would remain the most used antimicrobial classes in
-
I11 | Evolution of European Union legislation on antimicrobials: Objectives to be achieved and consequences for prescribers J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-06-11
D. Bouchard French Agency for Food, Environmental, and Occupational Health and Safety, National Agency for Veterinary Medicinal Products, Fougères, France The European One Health Action Plan against Antimicrobial Resistance (AMR), adopted in 2017, recognizing the burden of AMR has defined a framework for concrete actions, some of which were ratified as measures during the regulatory revision related
-
I12 | Anthelmintics and ion-channels J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-06-11
R. J. Martin; S. S. Kashyap; P. D. E. Williamson; M. McHugh; S. Choudhary; A. P. Robertson Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, Iowa, USA Introduction: There are a limited number of classes of anthelmintic drugs and there are increasing concerns about the development of resistance. The development of novel anthelmintic drugs is slow, in part
-
I13 | Responsible use of anthelmintics in livestock: Pharmacology-based contribution to the management of drug resistance J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-06-11
C. Lanusse Laboratorio de Farmacología, Centro de investigación Veterinaria de Tandil (CIVETAN), CONICET-CICPBA-Universidad Nacional del Centro, Tandil, Argentina The Keynote Lecture to be presented at the 2023 EAVPT Congress will emphasize on how the use of pharmacology-based information may be critical to achieve sustainable parasite control. The inadequate use of anthelmitics has led to therapeutic
-
I14 | From the bench to the exam room: Development of anti-NGF mAbs for the treatment of pain associated with osteoarthritis J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-06-11
S. Knauer Zoetis, Veterinary Medicine Research and Development, Kalamazoo, Michigan, USA While monoclonal antibodies (mAbs) have been widely used for decades to treat various diseases in human medicine, their application as therapeutics in veterinary medicine has been limited by comparison. The first veterinary mAb, lokivetmab (Cytopoint®), was developed to target and neutralize interleukin-31 and
-
I15 | Update on immune modulators for the treatment of allergic diseases in veterinary medicine J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-06-11
W. Bäumer Institute of Pharmacology and Toxicology, School of Veterinary Medicine, Freie Universität Berlin, Germany For a long time, glucocorticoids and, to a lesser extent, anti-histamines have been the main therapeutic options for allergic diseases in veterinary medicine. However, in recent years, new developments have broadened the therapeutic options for allergic diseases. With regard to allergic
-
I16 | Virus-free engineering of CAR-T cell therapy for companion canines J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-06-11
W. Wierson LEAH Labs, Rochester, USA While Chimeric Antigen Receptor (CAR)-T cell therapy has revolutionized the treatment of hematologic malignancies in humans, outcomes could be enhanced and accessibility vastly improved. All FDA-approved CAR-T cell therapies are currently autologous transplants and genetically reprogrammed using lentivirus. These factors contribute to critical limitations in patient
-
I17 | Gene editing and gene therapy: Perspectives for the future of veterinary medicine in the ‘CRISPR era’ J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-06-11
W. Wierson LEAH Labs, Rochester, USA With rapid advances in gene therapy and gene editing technologies, the development of genetic-, cell-, or protein-based cures to disease is no longer in the realm of science fiction. Most simply, gene therapy involves the random transfer of a full length, healthy copy of a gene into a diseased cell, where gene editing allows scientists to either specifically target
-
I18 | Comparative approaches to improve efficacy and availability of cellular therapies for cancer patients J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-06-11
J. Nicola; B. Mason Department of Clinical Sciences and Advanced Medicine and Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA Adoptive cellular therapies (ACT) in the form of engineered autologous T cell products have changed the landscape of human cancer therapy and similar “living therapy” approaches are slated to provide therapeutic advances
-
I19 | Ghent University's Veterinary Oncology Network: Towards solutions for human and veterinary cancer patients J. Vet. Pharmacol. Thera. (IF 1.3) Pub Date : 2023-06-11
L. Cicchelero Ghent University, Ghent, Belgium Companion animal oncology is a growing field of research. The past decennia, companion animal veterinary medicine experienced a remarkable evolution, with human medical technologies increasingly finding their applications in veterinary medicine. Vice versa, companion animals develop cancer spontaneously in an intact immune system and represent a valuable